Skip to main content Skip to navigation

Professor David Fitzmaurice

Job Title
WMS - Health Sciences
02476 151129
Research Interests

Professor Fitzmaurice's research interests are in cardiovascular and respiratory disease. His original work investigating service redesign of oral anticoagulation services has grown into a large programme of work around detection and treatment of atrial fibrillation and includes an on-going NIHR programme grant investigating how to improve diagnosis and treatment of venous thromboembolism. He has been instrumental in developing self-management for patients receiving warfarin treatment and is a leading authority on the implementation of new oral anticoagulation therapies in the UK. His respiratory interests grew from an early study investigating the clinical effectiveness of different inhaler devices for the treatment of asthma and he currently leads an NIHR programme grant investigating the effectiveness of screening for COPD, with a particular focus on early stage disease.


Professor David Fitzmaurice qualified from the University of Birmingham Medical School in 1987. He was appointed as the first academic trainee GP in 1993 David joined the Health Sciences research division at Warwick Medical School, University of Warwick in October 2016. He continues to undertake two sessions of clinical practice per week in an inner city general practice. He has published extensively in and represents Primary Care on many national and international bodies. He has been involved in several large scale studies and has published around 150 papers in peer-reviewed publications. His main research interest has been in the area of anticoagulation research, particularly focussing on the primary care management of oral anticoagulation and venous thromboembolic disease. This work has led to the "Birmingham Model" of oral anticoagulation management, comprising a practice nurse led clinic utilising near patient testing for INR measurement and computerised decision support software to assist with dosing, being recognised both nationally and internationally as a credible alternative to the traditional hospital out-patient model of oral anticoagulation management. This, in turn has led to the development of the concept of patient self-management of oral anticoagulation with the SMART trial, an MRC funded trial of self-management versus routine care, demonstrating the clinical effectiveness of this model within the UK. He was PI on the landmark BAFTA study which demonstrated the superiority of warfarin over aspirin as stroke prevention for patients aged 75 and over with atrial fibrillation. The relative success of this programme of work was recognised with an NHS Career Scientist Award in 1999.He has been invited to speak at numerous national and international scientific meetings of primary care, cardiology and haematology, for example, the Society for Academic Primary Care, the North American Primary Care Research Group, The British Cardiac Society, the British Society for Haematology, The International Society for Haemostasis and Thrombosis. He represents Primary Care on various national and international bodies with an interest in these areas, very often being the only primary care input into specialist organisations, for example, the British Committee for Standards in Thrombosis and Haemostasis (BCSTH), the International Society for Anticoagulation At home Monitoring (ISAAM), The Royal College of General Practitioners Research Group. More recent work has included investigations into the genetic basis of warfarin sensitivity, performance evaluations of diagnostic tests and registry based studies around atrial fibrillation and patient self-management of oral anticoagulation. He was a member of the NICE Guideline Development Group for Atrial Fibrillation (reported 2014), and more recently for Non-Alcoholic Liver Disease. He is currently an expert advisor to the NICE Centre for Clinical Practice and a board member of the NIHR PCCPI panel. In parallel with his research, Professor Fitzmaurice has developed an extensive programme of Post-Graduate Teaching, both accredited and Non-Accredited.

Title Funder Award start Award end
NIHR HTA 2nd stage via UoB: Sputum Colour Charts To Guide Antibiotic Self-treatment Of Acute Exacerbation Of COPD" National Institute for Health Research (DoH) 01 Dec 2019 30 Nov 2023
NIHR HTA:Aspirin To Target Arterial Events In Chronic Kidney Disease (ATTACK)" National Institute for Health Research (DoH) 01 Jan 2018 31 Dec 2022
NIHR HTA Second Stage: Exercise training in pulmonary hypertension National Institute for Health Research (DoH) 01 Jun 2019 31 Aug 2022
Screening for AF National Institute for Health Research (DoH) 01 Oct 2018 31 Oct 2021
GARFIELD AF: Costing for 6 month extension to 60673 National Institute for Health Research (NIHR DoH) 01 Mar 2021 31 Aug 2021
NIHR RfPB 2nd stage. GARFIELD-AF in Primary Care - Optimising prediction of mortality, stroke, and major bleeding for patients with atrial fibrillation using routinely collected primary care electronic health records (Stage 1 - 58973) National Institute for Health Research (DoH) 01 Mar 2020 28 Feb 2021
Garfield Ideate records for payments to GP's Thrombosis Research Institute 02 May 2017 01 May 2019
GARFIELD: Extension: Linked to IDEATE record 53260 Thrombosis Research Institute 01 Sep 2018 28 Feb 2019
Prospective, multicentre, international Registry of male and female patients newly diagnosed with atrial fibrillation (GARFIELD) Thrombosis Research Institute 05 Jan 2017 04 Jan 2019